Study Summary: FLAME

Published Online: March 17, 2017
Study Summary: FLAME
Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD exacerbations. N Engl J Med. 2016;374(23):2222-2234. doi: 10.1056/NEJMoa1516385.
Exacerbations are episodes of chronic obstructive pulmonary disease (COPD) worsening characterized by declines in both lung function and quality of life. Minimizing exacerbation risk is 1 of the primary goals of long-term care for patients with COPD, as exacerbations increase hospitalization risk and COPD-related mortality. Current clinical treatment guidelines for patients with COPD at high risk of exacerbations recommend the combination of a long-acting beta2-agonist (LABA) with an inhaled glucocorticoid (also called an inhaled corticosteroid, or ICS) or a long-acting muscarinic antagonist (LAMA) monotherapy as first-line therapy. However, in patients with severe COPD, these first-line therapy options have demonstrated similar high rates of annual exacerbation. Thus, additional treatment options are needed to prevent COPD exacerbations in patients with severe COPD. A regimen with dual bronchodilators is a potential alternative treatment in these patients. Previously, a LABA/LAMA combination was shown to be more effective than LAMA monotherapy in reducing exacerbation rates; however, previous studies were not powered to show LABA/LAMA exacerbation benefit over LABA/ICS.1
The Effect of Indacaterol–Glycopyrronium Versus Fluticasone–Salmeterol on COPD Exacerbations (FLAME) trial investigated whether a once-daily LABA/LAMA treatment would be at least as effective as twice-daily LABA/ICS therapy in the reduction of exacerbations in patients with COPD. Investigators evaluated COPD exacerbations through electronic diaries in which patients documented symptom worsening and medication use each day. Mild exacerbations were characterized by worsening of symptoms for greater than 2 consecutive days without need for treatment. Moderate and severe COPD exacerbations were those that led to treatment with systemic glucocorticoids and/or antibiotics; in addition, to be classified as severe, exacerbations required a hospital admission or emergency department visit longer than 24 hours. From July 2013 to September 2015, the FLAME trial enrolled a total of 3362 patients with COPD 40 years and older with a history of least 1 exacerbation requiring treatment within the previous year. Nearly three quarters (74.8%) of patients had a high exacerbation risk with a high burden of symptoms, based on the 2015 Global Initiative for Chronic Obstructive Lung Disease staging system. During this 52-week trial, patients with COPD were randomized (1:1) to receive either dual bronchodilator therapy (110 μg indacaterol [LABA] and 50 μg glycopyrronium [LAMA], combination once daily) or bronchodilator plus inhaled corticosteroid (ICS) therapy (50 μg salmeterol [LABA] and 500 μg fluticasone [ICS], combination twice daily).1
With regard to the primary outcome, dual bronchodilation therapy with indacaterol and glycopyrronium was shown to be noninferior, as well as superior, to salmeterol and fluticasone treatment in reducing the annual rate of mild, moderate, and severe COPD exacerbations (Figure1). Noninferiority and superiority were achieved when the upper limit of the 95% confidence interval (CI) of the rate ratio (RR) for exacerbations was less than 1.15 and did not exceed 1, respectively. The annual rate of all COPD exacerbations was reduced by 11% in the indacaterol and glycopyrronium treatment arm compared with salmeterol and fluticasone (RR, 0.89; 95% CI, 0.83-0.96; P = .003). The rate of moderate or severe COPD exacerbations was significantly reduced by 17% (P <.001) with indacaterol and glycopyrronium treatment compared with the salmeterol and fluticasone regimen (RR, 0.83; 95% CI, 0.75-0.91).1

With regard to secondary outcomes, dual bronchodilation therapy significantly delayed the time to first COPD exacerbation onset compared with salmeterol and fluticasone. During the 52-week trial, less than 50% of patients treated with indacaterol and glycopyrronium experienced an exacerbation. Treatment with indacaterol and glycopyrronium significantly (P <.001) prolonged time to a COPD exacerbation of any severity (71 days vs 51 days) and time to the first moderate or severe COPD exacerbation (127 days vs 87 days). Patients in the indacaterol and glycopyrronium arm had a lower risk of all severity (16%), moderate or severe (22%), and severe (19%) exacerbations.1
After 52 weeks of therapy, pulmonary function was assessed by the mean change from the baseline value of trough forced expiratory volume in 1 second (FEV1) between groups. Once-daily indacaterol and glycopyrronium treatment lead to significant (P <.001) improvements in lung function compared with treatment with salmeterol and fluticasone, with a mean FEV1 change of +62 mL. Health status improvement was measured by a clinically relevant decrease of at least 4 points in the total score on the St. George’s Respiratory Questionnaire for COPD (SGRQ-C) following 52 weeks of treatment, compared with baseline. A significantly higher (P <.001) percentage of patients in the indacaterol and glycopyrronium arm (49.2%) had SGRQ-C score decreases of at least 4 points compared with the salmeterol and fluticasone group (43.7%). Based on these data, investigators concluded that the combination of 2 bronchodilators improves lung function and health status to a greater degree than LABA/ICS therapy.1
Rates of adverse events (AEs) were similar across treatment groups: 86.9% and 89.2% of patients experienced at least 1 AE in the indacaterol and glycopyrronium arm and the salmeterol and fluticasone arm, respectively. Serious AEs occurred in 18.4% of patients treated with indacaterol and glycopyrronium, and in 19.9% of patients receiving salmeterol and fluticasone. A mortality rate of 1.4% was observed in each treatment group. Because previous studies have indicated the association between long-term glucocorticoid use and pneumonia risk, FLAME trial investigators evaluated the risk of pneumonia, and noted a significantly (P = .02) lower incidence of pneumonia with indacaterol and glycopyrronium treatment compared with salmeterol and fluticasone (3.2% vs 4.8%).1
FLAME study investigators concluded that the once-daily combination LABA/LAMA therapy of indacaterol and glycopyrronium was superior to the LABA/ICS combination of salmeterol and fluticasone in reducing the rate of COPD exacerbations of all severity levels, as well as in improving lung function and health status, with similar AE rates. Investigators noted that the success of this trial may have implications for current clinical guidelines and recommendations for COPD management in patients with a history of exacerbation. Future clinical trials investigating additional combinations of long-acting bronchodilators may provide further evidence of LABA/LAMA regimen superiority and support its use as first-line therapy in this population of patients with COPD.1
1. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD exacerbations. N Engl J Med. 2016;374(23):2222-2234. doi: 10.1056/NEJMoa1516385.
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST